BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20307913)

  • 21. Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
    Katayama T; Matsuo K; Kosaka T; Sueda T; Yatabe Y; Mitsudomi T
    Surg Oncol; 2010 Dec; 19(4):e144-9. PubMed ID: 20705455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
    Ruppert AM; Beau-Faller M; Neuville A; Guerin E; Voegeli AC; Mennecier B; Legrain M; Molard A; Jeung MY; Gaub MP; Oudet P; Quoix E
    Eur Respir J; 2009 Feb; 33(2):436-40. PubMed ID: 19181917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and molecular analysis of synchronous double lung cancers.
    Arai J; Tsuchiya T; Oikawa M; Mochinaga K; Hayashi T; Yoshiura K; Tsukamoto K; Yamasaki N; Matsumoto K; Miyazaki T; Nagayasu T
    Lung Cancer; 2012 Aug; 77(2):281-7. PubMed ID: 22560922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung.
    Haneda H; Sasaki H; Shimizu S; Endo K; Suzuki E; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Lung Cancer; 2006 Apr; 52(1):47-52. PubMed ID: 16503085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and management of synchronous lung cancers.
    Ferguson MK; DeMeester TR; DesLauriers J; Little AG; Piraux M; Golomb H
    J Thorac Cardiovasc Surg; 1985 Mar; 89(3):378-85. PubMed ID: 3974273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
    Rai K; Fujiwara K; Tsushima M; Kudo K; Mizuta M; Matsuo K; Yonei T; Yamadori I; Kiura K; Sato T
    Jpn J Clin Oncol; 2011 Sep; 41(9):1138-41. PubMed ID: 21835826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4 years after sublobar resection for adenocarcinoma in situ: report of a case.
    Isaka T; Yokose T; Ito H; Imamura N; Watanabe M; Imai K; Nishii T; Yamada K; Nakayama H; Masuda M
    Surg Today; 2015 Oct; 45(10):1330-4. PubMed ID: 25377270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
    Balak MN; Gong Y; Riely GJ; Somwar R; Li AR; Zakowski MF; Chiang A; Yang G; Ouerfelli O; Kris MG; Ladanyi M; Miller VA; Pao W
    Clin Cancer Res; 2006 Nov; 12(21):6494-501. PubMed ID: 17085664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
    Onitsuka T; Uramoto H; Nose N; Takenoyama M; Hanagiri T; Sugio K; Yasumoto K
    Lung Cancer; 2010 May; 68(2):198-203. PubMed ID: 19589612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
    Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
    Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
    Hasanovic A; Ang D; Moreira AL; Zakowski MF
    Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discrimination of multiple primary lung cancers from intrapulmonary metastasis based on the expression of four cancer-related proteins.
    Ono K; Sugio K; Uramoto H; Baba T; Ichiki Y; Takenoyama M; Hanagiri T; Oyama T; Yasumoto K
    Cancer; 2009 Aug; 115(15):3489-500. PubMed ID: 19452548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
    Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
    Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.
    Yoshida Y; Shibata T; Kokubu A; Tsuta K; Matsuno Y; Kanai Y; Asamura H; Tsuchiya R; Hirohashi S
    Lung Cancer; 2005 Oct; 50(1):1-8. PubMed ID: 15950315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
    Wu JY; Wu SG; Yang CH; Chang YL; Chang YC; Hsu YC; Shih JY; Yang PC
    Lung Cancer; 2011 May; 72(2):205-12. PubMed ID: 20832137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
    Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
    J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.